Veriskin

Veriskin, Inc., headquartered in San Diego, California, USA, is dedicated to developing new tools for primary care practitioners and dermatologists to help assess whether suspicious skin lesions may potentially develop into cancer. Veriskin's mission is to improve patient outcomes and reduce healthcare costs by enhancing diagnostic accuracy. Veriskin's TruScore is a proprietary, non-invasive, low-cost handheld device that assists non-specialist users in quickly and objectively determining whether suspicious skin lesions are cancerous. It is suitable for both pigmented and non-pigmented skin lesions and generates a quantitative score. The use of this device can potentially reduce missed cancers and the number of unnecessary biopsies.